General MedicationsNASALStandard
TYRVAYA
VARENICLINE TARTRATE
Standard Dose
EQ 0.03MG BASE/SPRAY
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview TYRVAYA is listed in Drugs@FDA under application 213978 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient VARENICLINE TARTRATE Form and strength SPRAY;NASAL - EQ 0.03MG BASE/SPRAY Sponsor OYSTER POINT PHARMA Submission history Latest submission status date: 2024-02-02 00:00:00.
Structured Monograph
Clinical summary
Approval overview TYRVAYA is listed in Drugs@FDA under application 213978 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient VARENICLINE TARTRATE Form and strength SPRAY;NASAL - EQ 0.03MG BASE/SPRAY Sponsor OYSTER POINT PHARMA Submission history Latest submission status date: 2024-02-02 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.